HGH 191AA

HGH 191AA (Somatropin) – Human Growth Hormone Research

Recombinant 191-Amino-Acid Growth Hormone for GH Receptor Signaling, IGF-1 Regulation, Growth Physiology & Metabolic Research

HGH 191AA, also known as human growth hormone (hGH) or somatropin, refers to the 191-amino-acid form of human growth hormone, a protein hormone that plays a central role in growth, metabolism and endocrine regulation.

The predominant form of human pituitary growth hormone is a single-chain protein containing 191 amino acid residues and having an approximate molecular mass of 22 kilodaltons (kDa).

Growth hormone is naturally produced by somatotroph cells in the anterior pituitary gland. Its secretion is regulated by hypothalamic growth hormone-releasing hormone (GHRH), somatostatin, ghrelin-associated signaling and multiple physiological feedback mechanisms.

Unlike growth hormone-releasing peptides such as GHRP-2, GHRP-6 and Hexarelin, HGH 191AA is not a growth hormone secretagogue.

It is the growth hormone molecule itself.

HGH 191AA interacts directly with the growth hormone receptor (GHR), activating intracellular signaling pathways that include Janus kinase 2 (JAK2) and signal transducer and activator of transcription 5 (STAT5).

These pathways influence insulin-like growth factor-1 (IGF-1) production and several processes involved in growth and metabolism.

Recombinant human growth hormone has an established history in clinical medicine, including authorized treatments for specific growth hormone-related disorders.

However, medically authorized somatropin preparations must be distinguished from research-grade products.

ICAME Pharmacy HGH 191AA is intended strictly for laboratory research and development purposes. Not for human or veterinary use.

What Is HGH 191AA?

HGH 191AA is the full-length 191-amino-acid form of human growth hormone.

The abbreviation HGH stands for Human Growth Hormone, while 191AA refers to its amino acid length.

Human growth hormone belongs to the somatotropin family of protein hormones.

Its principal biological functions include the regulation of:

• Linear growth

• IGF-1 production

• Protein metabolism

• Lipid metabolism

• Glucose homeostasis

• Bone growth and remodeling

• Cartilage physiology

• Tissue growth

• Endocrine feedback

• Body composition

• Cellular growth signaling

The term somatropin is generally used for recombinant human growth hormone pharmaceutical preparations.

Although a research material may be described as HGH 191AA, this designation alone does not establish that it has the same quality, biological activity, formulation or regulatory status as an approved somatropin medicine.

HGH 191AA Molecular Structure

Human growth hormone is a single-chain polypeptide composed of 191 amino acid residues.

Its three-dimensional structure consists predominantly of alpha-helical regions arranged in a characteristic four-helix bundle.

The protein contains two intramolecular disulfide bonds that contribute to structural stability.

Molecular Characteristics

Compound Name: Human Growth Hormone

Common Abbreviation: HGH / hGH

Pharmaceutical Name: Somatropin

Classification: Protein Hormone

Protein Length: 191 Amino Acid Residues

Approximate Molecular Weight: 22,125 Da (22.1 kDa)

Molecular Formula: C₉₉₀H₁₅₂₈N₂₆₂O₃₀₀S₇

Commonly Referenced CAS Number: 12629-01-5 (Somatropin)

Primary Receptor: Growth Hormone Receptor (GHR)

Principal Signaling Pathway: JAK2–STAT5

Primary Endocrine Axis: GH–IGF-1

Natural Production Site: Anterior Pituitary Gland

The formula and molecular mass refer to the commonly described 191-amino-acid human GH protein.

Research products may differ in purity, folding, aggregation state, formulation and biological potency.

A molecular formula or peptide sequence alone cannot establish functional equivalence to an approved pharmaceutical preparation.

HGH 191AA Amino Acid Sequence

The mature 191-amino-acid human growth hormone sequence is:

FPTIPLSRLF DNAMLRAHRL HQLAFDTYQE FEEAYIPKEQ KYSFLQNPQT SLCFSESIPT PSNREETQQK SNLELLRISL LLIQSWLEPV QFLRSVFANS LVYGASDSNV YDLLKDLEEG IQTLMGRLED GSPRTGQIFK QTYSKFDTNS HNDDALLKNY GLLYCFRKDM DKVETFLRIV QCRSVEGSCG F

The spaces are included only to improve readability.

This sequence corresponds to the mature 191-residue human GH protein.

Correct primary sequence is necessary but not sufficient for biological activity. Proper protein folding, disulfide bond formation and structural integrity are also important.

Discovery and Development of Human Growth Hormone

Growth hormone research developed from early investigations into the endocrine functions of the pituitary gland.

Scientists identified the anterior pituitary as a major source of hormones regulating growth and metabolism.

Early human growth hormone preparations were extracted from human pituitary tissue.

The development of recombinant DNA technology transformed growth hormone production by allowing the hormone to be manufactured without relying on human pituitary extraction.

Recombinant human growth hormone subsequently became an important pharmaceutical product for selected endocrine disorders.

The development of somatropin also contributed to scientific understanding of protein hormone manufacturing, receptor signaling and growth physiology.

Today, human GH remains an important subject of research in endocrinology, molecular biology and metabolic physiology.

How Does HGH 191AA Work?

HGH 191AA exerts its biological effects primarily through the growth hormone receptor (GHR).

GHR belongs to the class I cytokine receptor family.

When growth hormone binds to the receptor, it promotes a conformational rearrangement of receptor-associated signaling components.

This activates intracellular pathways, particularly the JAK2–STAT5 signaling cascade.

Simplified Mechanism of Action

HGH 191AA

↓

Growth Hormone Receptor (GHR) Binding

↓

Receptor Conformational Rearrangement

↓

JAK2 Activation

↓

STAT5 Phosphorylation

↓

STAT5 Dimerization and Nuclear Translocation

↓

Regulation of Gene Transcription

↓

IGF-1 Production and Other GH-Responsive Processes

The biological effects of growth hormone are not limited to one pathway.

Additional signaling systems can participate in tissue-specific responses.

HGH 191AA and the Growth Hormone Receptor

The growth hormone receptor is expressed in multiple tissues.

These include the liver, skeletal muscle, adipose tissue and growth-related tissues.

Receptor activation contributes to both direct and indirect effects of growth hormone.

Direct GH Effects

Growth hormone can influence cellular metabolism and signaling through direct interaction with GHR.

Indirect GH Effects

Growth hormone stimulates IGF-1 production in the liver and other tissues.

IGF-1 subsequently acts through its own receptor-mediated signaling pathways.

This distinction is important because not every physiological effect of GH is mediated exclusively by circulating IGF-1.

HGH 191AA and JAK2–STAT5 Signaling

The JAK2–STAT5 pathway is one of the most important intracellular mechanisms associated with GH receptor activation.

JAK2 is a receptor-associated tyrosine kinase.

STAT5 is a transcription factor involved in regulating gene expression.

Following GH receptor activation, JAK2 phosphorylates signaling proteins, including STAT5.

Activated STAT5 can move into the nucleus and influence transcription of GH-responsive genes.

Relevant research areas include:

Receptor phosphorylation

JAK2 kinase activity

STAT5 activation

Gene transcription

IGF-1 regulation

Cellular growth signaling

Negative feedback mechanisms

This pathway is central to understanding both normal GH physiology and disorders involving impaired GH signaling.

HGH 191AA and Additional Signaling Pathways

Although JAK2–STAT5 is a principal pathway, growth hormone signaling is more complex.

Experimental studies have also investigated interactions involving:

MAPK/ERK signaling

PI3K-associated pathways

Insulin receptor substrate proteins

SOCS-mediated negative feedback

Other intracellular kinase systems

The relative importance of these pathways depends on cell type, physiological conditions and experimental model.

It is therefore important not to assume that every pathway observed in cultured cells is activated identically in human tissues.

HGH 191AA and the GH–IGF-1 Axis

The GH–IGF-1 axis is a central endocrine system involved in growth and metabolism.

Growth hormone stimulates IGF-1 production, particularly in the liver.

IGF-1 can act through endocrine, paracrine and autocrine mechanisms.

GH–IGF-1 Axis Overview

Hypothalamus

↓

GHRH / Somatostatin Regulation

↓

Anterior Pituitary

↓

Growth Hormone Secretion

↓

GH Receptor Activation

↓

Liver and Peripheral Tissues

↓

IGF-1 Production

↓

Growth-Associated Cellular Signaling

↓

Feedback Regulation

Circulating IGF-1 participates in negative feedback regulation of the GH axis.

This relationship helps maintain endocrine homeostasis.

HGH 191AA and IGF-1 Research

Insulin-like growth factor-1 (IGF-1) is a peptide growth factor involved in tissue growth, cellular signaling and metabolic regulation.

GH is an important regulator of IGF-1 production.

However, IGF-1 levels are also influenced by:

• Age

• Nutritional status

• Liver function

• Endocrine disorders

• Physiological development

• Inflammatory and metabolic conditions

HGH 191AA is relevant to research investigating how GH receptor activation influences IGF-1 expression.

The relationship between GH and IGF-1 is important in both growth hormone deficiency and growth hormone resistance.

HGH 191AA and Growth Plate Physiology

Linear growth in children occurs primarily through specialized cartilage structures called epiphyseal growth plates.

These structures contain chondrocytes that undergo proliferation, differentiation and maturation.

Growth hormone and IGF-1 participate in the regulation of growth plate physiology.

Research areas include:

Chondrocyte proliferation

Cartilage matrix production

Cellular differentiation

Longitudinal bone growth

Growth factor signaling

Endocrine regulation

Growth hormone cannot produce additional longitudinal bone growth after the growth plates have fully fused.

This distinction is essential when discussing HGH and adult height.

HGH 191AA and Bone Research

Growth hormone participates in skeletal development and bone metabolism.

It can influence bone-related signaling both directly and through IGF-1.

Relevant research topics include:

Bone formation

Osteoblast biology

Bone remodeling

Cartilage physiology

Skeletal development

IGF-1-associated bone signaling

However, effects on bone metabolism depend on age, hormonal status and underlying medical conditions.

Changes in bone turnover markers do not automatically establish a reduction in fracture risk.

HGH 191AA and Skeletal Muscle Research

Growth hormone influences protein metabolism and body composition.

In individuals with established GH deficiency, authorized somatropin treatment may improve certain body composition measures.

However, these findings should not be generalized to healthy individuals with normal GH function.

Growth hormone-associated increases in lean body mass may partly reflect changes in extracellular water rather than increases in contractile muscle tissue.

Controlled research in healthy adults has not consistently demonstrated meaningful improvements in muscle strength or athletic performance.

Relevant research areas include:

Protein turnover

Muscle metabolism

GH receptor expression

IGF-1-associated signaling

Body composition

Exercise endocrinology

Cellular growth pathways

HGH 191AA should not be described as a proven muscle-building treatment for healthy individuals.

HGH 191AA and Adipose Tissue Research

Growth hormone participates in the regulation of lipid metabolism.

One of its recognized metabolic effects is the promotion of lipolytic activity under appropriate physiological conditions.

Lipolysis involves the breakdown of stored triglycerides into fatty acids and glycerol.

Research involving HGH 191AA includes:

Adipocyte signaling

Lipid mobilization

Fatty acid metabolism

Body composition

Energy balance

GH receptor activity in adipose tissue

However, an increase in lipolysis does not automatically establish safe or sustained weight loss.

Growth hormone also affects glucose regulation and can reduce insulin sensitivity.

Consequently, its metabolic effects must be considered together rather than presenting lipid-related activity as an isolated benefit.

HGH 191AA and Glucose Metabolism

Growth hormone influences glucose homeostasis through multiple mechanisms.

GH can oppose certain actions of insulin, particularly in relation to glucose utilization and metabolic substrate availability.

Excessive GH exposure can contribute to insulin resistance and elevated blood glucose.

Research areas include:

Insulin sensitivity

Glucose homeostasis

Hepatic glucose metabolism

Adipose tissue signaling

Metabolic feedback

Endocrine interactions

These effects are particularly relevant when evaluating the safety of GH-related interventions.

HGH should not be described as a general-purpose metabolic health enhancer.

HGH 191AA and Protein Metabolism

Growth hormone participates in the regulation of protein turnover.

Its effects can include changes in amino acid utilization and protein synthesis-associated processes.

Research has examined these effects in:

Skeletal muscle

Connective tissue

Liver

Growth-related tissues

Experimental cellular systems

However, increased protein synthesis-related signaling does not automatically establish functional improvements in strength, recovery or physical performance.

HGH 191AA and Connective Tissue Research

Growth hormone and IGF-1 are involved in biological processes relevant to connective tissue.

Research has investigated their effects on collagen metabolism and extracellular matrix regulation.

Potential research topics include:

Collagen synthesis

Extracellular matrix biology

Tendon-associated metabolism

Ligament physiology

Tissue remodeling

Growth factor signaling

However, increased collagen-related biomarkers do not establish that HGH prevents injuries or accelerates healing in healthy humans.

Clinical outcomes require separate investigation.

HGH 191AA and Endocrine Feedback

Growth hormone secretion is naturally pulsatile.

Its regulation involves interactions among:

GHRH

Somatostatin

Ghrelin

GH

IGF-1

Metabolic signals

Sleep-associated physiology

IGF-1 and GH participate in feedback mechanisms that regulate further GH secretion.

Exogenous growth hormone can influence these feedback systems.

This is one reason why externally supplied GH is physiologically different from compounds that stimulate endogenous pituitary GH release.

HGH 191AA and Sleep-Associated GH Physiology

GH secretion is associated with sleep physiology.

In many individuals, a prominent GH pulse occurs during the early part of nocturnal sleep.

This secretion is associated with slow-wave sleep.

Research has investigated the relationship between:

Sleep architecture

GH pulsatility

Hypothalamic signaling

Metabolic regulation

Endocrine rhythms

However, the relationship between GH and sleep is complex.

It does not establish HGH 191AA as an effective treatment for insomnia or as a reliable sleep-quality enhancer.

HGH 191AA and Age-Related Endocrine Changes

GH secretion and circulating IGF-1 concentrations generally change with age.

These changes have generated interest in the relationship between the GH–IGF-1 axis and aging.

Research areas include:

Age-associated endocrine changes

Body composition

Metabolic physiology

Bone health

Muscle function

Hormonal feedback

However, age-related declines in GH do not automatically represent a disease requiring treatment.

Evidence does not establish growth hormone treatment as a safe or effective strategy for extending lifespan or reversing normal aging.

Potential adverse effects are particularly important when evaluating GH use in otherwise healthy older adults.

HGH 191AA and Growth Hormone Deficiency Research

Growth hormone deficiency (GHD) occurs when the body produces insufficient GH for its physiological requirements.

GHD may develop during childhood or adulthood.

Possible causes include hypothalamic or pituitary disorders, genetic conditions, structural abnormalities and acquired pituitary disease.

Childhood GHD

GH deficiency during childhood can impair normal growth.

Adult GHD

Adult GH deficiency can be associated with changes in body composition, metabolic parameters and quality of life.

Clinical Context

Recombinant human growth hormone is an established treatment for appropriately diagnosed GH deficiency in selected patients.

Treatment requires medical evaluation, approved pharmaceutical products and clinical monitoring.

A research-grade HGH 191AA preparation is not an alternative to authorized treatment.

HGH 191AA and Approved Somatropin Therapies

Recombinant somatropin is used in clinical medicine for specific indications.

Depending on the country and individual product authorization, these may include:

Pediatric growth hormone deficiency

Adult growth hormone deficiency

Turner syndrome-associated growth disorders

Growth failure associated with selected genetic conditions

Children born small for gestational age without adequate catch-up growth

Other product-specific authorized indications

These uses are supported by clinical trials and regulatory evaluations of specific pharmaceutical preparations.

Approval for one somatropin product does not automatically apply to every recombinant HGH preparation.

Research-grade materials cannot be considered therapeutically interchangeable with licensed medicines.

HGH 191AA and Recombinant Protein Production

Modern recombinant human growth hormone is manufactured using biotechnology.

Production typically involves expression of a recombinant protein in a suitable biological system, followed by purification and analytical characterization.

Manufacturing quality is especially important for protein hormones because biological activity depends on more than amino acid sequence.

Relevant research and quality-control considerations include:

Protein identity

Amino acid sequence

Correct folding

Disulfide bond integrity

Purity

Protein aggregation

Biological potency

Host-cell protein impurities

Endotoxin content

Product stability

Analytical confirmation of identity and purity does not by itself establish sterility, pharmaceutical suitability or clinical safety.

HGH 191AA and Protein Folding

Proteins depend on their three-dimensional structure for biological function.

Human growth hormone contains alpha-helical regions that form a compact structure.

Its disulfide bonds contribute to maintaining the correct conformation.

Improper folding may reduce receptor binding or biological activity.

Protein aggregation can also alter product quality and may introduce additional safety concerns.

For this reason, research involving HGH 191AA may require analytical techniques capable of assessing both primary structure and higher-order protein integrity.

HGH 191AA and Analytical Characterization

Research-grade protein characterization may involve several analytical methods.

Mass Spectrometry

Used to investigate molecular identity and mass.

Chromatography

Used to evaluate purity and detect certain impurities or degradation products.

Electrophoretic Analysis

Used to assess protein size and selected quality characteristics.

Structural Analysis

Used to investigate protein conformation and aggregation.

Bioactivity Assays

Used to evaluate functional activity in appropriate experimental systems.

The specific methods and acceptance criteria should be documented for the relevant research material.

A Certificate of Analysis should be interpreted according to the actual tests performed rather than assumed to cover unreported quality attributes.

HGH 191AA vs. GHRP-2

HGH 191AA and GHRP-2 affect the GH axis through different mechanisms.

The two compounds are not interchangeable.

HGH 191AA vs. GHRP-6

GHRP-6 is a synthetic GH secretagogue.

It stimulates endogenous GH release through ghrelin receptor-associated signaling.

HGH 191AA directly activates GH receptors in target tissues.

GHRP-6 has also been investigated in appetite-associated research.

HGH 191AA has a broader direct role in GH receptor and IGF-1-associated physiology.

Their biological effects, pharmacology and clinical evidence differ substantially.

HGH 191AA vs. Hexarelin

Hexarelin is a synthetic growth hormone secretagogue that activates GHS-R1a-associated signaling.

It has also been investigated for cardiovascular effects and CD36-associated interactions.

HGH 191AA is the full-length growth hormone protein.

Its principal receptor is GHR.

Although both compounds relate to the GH axis, they do not act through identical pathways.

Research findings from Hexarelin cannot automatically be applied to HGH 191AA.

HGH 191AA vs. CJC-1295

CJC-1295 is a modified analogue of growth hormone-releasing hormone.

It activates the GHRH receptor and influences endogenous GH secretion.

HGH 191AA acts directly on GH receptors.

The compounds should not be considered therapeutically equivalent.

HGH 191AA vs. HGH Fragment 176–191

HGH 191AA and HGH Fragment 176–191 are fundamentally different molecules.

HGH 191AA contains the complete 191-amino-acid human GH sequence.

HGH Fragment 176–191 represents a short region derived from the C-terminal portion of human growth hormone.

The presence of a sequence derived from GH does not mean that a fragment reproduces the biological functions of the complete hormone.

HGH 191AA vs. IGF-1

Growth hormone and IGF-1 are different protein hormones with related physiological functions.

HGH activates the growth hormone receptor.

IGF-1 activates the IGF-1 receptor.

GH can stimulate IGF-1 production, but the two hormones have distinct receptor systems and biological effects.

HGH 191AA and Human Clinical Evidence

Human growth hormone is extensively studied compared with many experimental peptides.

Established Clinical Evidence

Authorized recombinant somatropin products have demonstrated efficacy in selected patients with appropriately diagnosed GH deficiency and other approved indications.

Body Composition

In GH-deficient patients, treatment can influence fat mass and lean body mass.

Growth

In children with selected growth disorders, authorized somatropin treatment can improve growth outcomes.

Metabolic Effects

Growth hormone affects glucose and lipid metabolism, with important implications for safety monitoring.

Healthy Adults

Evidence does not justify treating HGH as a general-purpose muscle-building, athletic-performance or anti-aging intervention.

Critical Distinction

Clinical findings from licensed somatropin medicines cannot automatically be attributed to an unverified HGH 191AA research preparation.

Potential Safety Concerns

Growth hormone is a potent endocrine regulator.

Its effects extend across multiple tissues and metabolic pathways.

Important safety concerns associated with pharmaceutical GH treatment include:

Glucose Intolerance and Diabetes

Growth hormone can reduce insulin sensitivity and contribute to abnormal glucose regulation.

Fluid Retention

Edema and other fluid-retention-related symptoms can occur.

Joint and Muscle Symptoms

Arthralgia, myalgia and related symptoms have been reported.

Carpal Tunnel Syndrome

Fluid retention may contribute to nerve compression symptoms.

Intracranial Hypertension

Intracranial hypertension has been reported with somatropin treatment.

Neoplasm-Related Concerns

Growth hormone therapy requires careful evaluation in patients with active malignancy or relevant cancer histories.

Pediatric Complications

Specific pediatric risks include slipped capital femoral epiphysis and progression of scoliosis during rapid growth.

Acute Critical Illness

Somatropin carries important warnings concerning certain acute critical illness settings.

Protein Quality and Immunogenicity

Impurities, aggregation and manufacturing differences may affect safety and biological activity.

Unverified Research Preparations

A research-grade product may lack the validated manufacturing controls and clinical quality standards required for human administration.

These considerations reinforce why HGH 191AA should not be promoted for unsupervised use.

HGH 191AA and Anti-Doping Regulations

Human growth hormone is prohibited under the World Anti-Doping Agency (WADA) framework.

It is included within the category covering peptide hormones, growth factors, related substances and mimetics.

GH is prohibited in sport both in and out of competition.

Athletes requiring legitimate treatment for a medical condition may need to follow the applicable Therapeutic Use Exemption process.

Research-product labeling does not exempt HGH from anti-doping restrictions.

Scientific Evidence and Research Limitations

HGH 191AA has a well-characterized physiological mechanism and an extensive research history.

However, the strength of evidence depends on the specific application.

Established Scientific Findings

• Human GH is a 191-amino-acid protein hormone.

• Its predominant pituitary form has an approximate mass of 22 kDa.

• It activates the growth hormone receptor.

• JAK2–STAT5 is a major GH signaling pathway.

• GH stimulates IGF-1 production.

• GH influences growth and metabolism.

• Authorized somatropin medicines have established clinical indications.

• GH can affect glucose regulation and insulin sensitivity.

Important Limitations

• HGH is not a proven general-purpose anti-aging treatment.

• GH-related changes in lean mass do not necessarily reflect increased muscle strength.

• Clinical evidence in GH-deficient patients cannot be generalized to healthy adults.

• Long-term inappropriate exposure can carry significant risks.

• Protein identity alone does not establish pharmaceutical quality.

• Research-grade HGH is not equivalent to licensed somatropin.

• Claims of sterility, potency and purity require product-specific documentation.

• HGH is prohibited in sport under anti-doping regulations.

Potential Research Applications

HGH 191AA may be relevant to appropriately controlled scientific investigations involving:

• Growth hormone receptor biology

• JAK2–STAT5 signaling

• GH–IGF-1 axis physiology

• Protein hormone pharmacology

• Growth plate biology

• Chondrocyte signaling

• Bone metabolism

• Skeletal muscle physiology

• Adipocyte signaling

• Lipid metabolism

• Glucose homeostasis

• Insulin sensitivity

• Protein metabolism

• Connective tissue biology

• Endocrine feedback

• Pituitary hormone physiology

• Growth hormone deficiency research

• Recombinant protein expression

• Protein folding and stability

• Biological potency assays

• Protein structure–function relationships

• GH receptor-mediated gene expression

These are scientific research applications, not claims of therapeutic benefit for a research-grade preparation.

HGH 191AA Research Overview

Compound Name: Human Growth Hormone

Alternative Name: Somatropin

Abbreviation: HGH / hGH

Classification: Protein Hormone

Amino Acid Length: 191

Molecular Formula: C₉₉₀H₁₅₂₈N₂₆₂O₃₀₀S₇

Approximate Molecular Weight: 22,125 Da

Common CAS Number: 12629-01-5

Primary Receptor: Growth Hormone Receptor (GHR)

Principal Signaling: JAK2–STAT5

Main Endocrine Axis: GH–IGF-1

Research Fields: Growth / Metabolism / Endocrinology / Protein Biology

Approved Clinical Applications: Specific licensed somatropin preparations and indications

ICAME Product Classification: Research Use Only

Anti-Doping Status: Prohibited under WADA rules

Product Information

Product Name: HGH 191AA

Full Name: Human Growth Hormone – 191 Amino Acids

Alternative Name: Somatropin

Brand: ICAME Pharmacy

Product Category: Research Protein / Peptide Hormone

Research Classification: Recombinant Human Growth Hormone

Research Areas: GH Receptor / JAK2–STAT5 / IGF-1 / Growth Physiology

Intended Use: Laboratory Research & Development Only

The exact identity and quality attributes of the supplied material should be verified through batch-specific manufacturer documentation.

Relevant information includes:

• Verified amino acid sequence

• Molecular identity

• Protein purity

• Biological activity

• Folding and structural integrity

• Protein aggregation

• Impurity profile

• Certificate of Analysis (COA)

• Batch/lot identification

• Validated storage conditions

No claims of pharmaceutical equivalence, sterility, injectable suitability or therapeutic efficacy should be made without appropriate supporting evidence and regulatory authorization.

Important Research Use Notice

FOR RESEARCH USE ONLY (RUO)

This ICAME Pharmacy product is intended exclusively for legitimate laboratory, analytical and scientific research purposes.

Not for human or veterinary use. Not for diagnostic, therapeutic, bodybuilding, weight-loss, performance-enhancing, anti-aging or other clinical purposes. Not for direct administration to humans or animals.

HGH 191AA is a biologically active human growth hormone protein.

Authorized somatropin medicines have established clinical applications, but those authorizations do not apply automatically to research-grade HGH preparations.

Growth hormone influences multiple endocrine and metabolic pathways and may produce serious adverse effects when used inappropriately.

HGH is prohibited in sport under WADA regulations.

Information presented on this page is intended solely for scientific and educational purposes and does not constitute medical advice, prescribing information, dosage guidance or instructions for human use.

About ICAME Pharmacy

ICAME Pharmacy provides specialized research products for professional laboratory and scientific applications.

Our portfolio focuses on compounds relevant to peptide science, endocrinology, molecular biology, receptor signaling, recombinant proteins and experimental pharmacology.

We emphasize accurate product identification, responsible research use, scientific transparency and clear communication of evidence limitations.

For batch-specific analytical documentation and product inquiries, please contact ICAME Pharmacy.

Frequently Asked Questions About HGH 191AA

What is HGH 191AA?

HGH 191AA is the full-length 191-amino-acid form of human growth hormone, a protein involved in growth, metabolism and IGF-1 regulation.

Is HGH 191AA the same as somatropin?

Somatropin is the pharmaceutical name commonly used for recombinant human growth hormone. However, a product labeled HGH 191AA is not automatically equivalent to an authorized somatropin medicine.

How many amino acids does HGH contain?

The predominant human pituitary GH form contains 191 amino acid residues.

What is the molecular weight of HGH 191AA?

Approximately 22.1 kDa.

What receptor does HGH activate?

Human growth hormone primarily activates the growth hormone receptor (GHR).

What is the main signaling pathway of HGH?

JAK2–STAT5 is a major signaling pathway associated with GH receptor activation.

Does HGH influence IGF-1?

Yes. Growth hormone stimulates IGF-1 production, particularly in the liver and other responsive tissues.

Is HGH 191AA the same as GHRP-2 or GHRP-6?

No. HGH 191AA is the growth hormone protein itself, whereas GHRP-2 and GHRP-6 are synthetic peptides that stimulate endogenous GH secretion.

Is HGH 191AA the same as HGH Fragment 176–191?

No. HGH 191AA is the complete protein, while HGH Fragment 176–191 is a short peptide derived from part of the GH sequence.

Is HGH approved for medical use?

Yes. Specific recombinant somatropin medicines are approved for defined medical indications in various jurisdictions. Research-grade HGH preparations are not automatically covered by those approvals.

Is HGH a proven anti-aging treatment?

No. Growth hormone has not been established as a safe or effective treatment for reversing normal aging.

Is HGH prohibited in sport?

Yes. Human growth hormone is prohibited under WADA anti-doping regulations.

Is ICAME Pharmacy HGH 191AA intended for human use?

No. ICAME Pharmacy HGH 191AA is intended strictly for laboratory research and development purposes.